Cristofanilli M, Slamon DJ, Ro J, et al. Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3. ESMO 2018, abstract LBA2_PR.
177Lu-Dotataat plus octreotide bij neuro-endocriene tumoren: NETTER-2
sep 2024 | Maag-darm-leveroncologie